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improve the treatment of atherosclerosis. This includes an 
increasing interest in using HDL as a therapeutic target.
HDL COMPOSITION, STRUCTURE, AND FUNCTION
HDL are heterogeneous complexes of proteins and 
lipids differing in shape (nascent discoidal or mature 
spherical), diameter (8–13 nm), density (1.21–1.063 g/ml), 
protein and lipid composition, and function.[8] Nascent 
discoidal HDL are comprised of a cholesterol-containing 
phospholipid bilayer surrounded by apolipoprotein 
α-helices.[9] Mature spherical HDL are composed of a 
monolayer of phospholipids and helical proteins on the 
surface and cholesterol ester as well as a small amount of 
triglycerides in the hydrophobic core.[10] Apolipoprotein 
A-I (apoA-I) is the major protein on HDL that accounts 
for ~70% of total HDL proteins. The second major 
protein, apoA-II, represents ~20%, and other HDL 
proteins, including apoE, apoA-IV, apoA-V, apoJ, apoC-I, 
apoC-II, and apoC-III, account for <10% of the HDL 
protein content.[11] Based on their density, mature HDL 
can be further divided into HDL2 (1.063–1.125 g/ml) and 
HDL3 (1.125–1.21 g/ml). These subclasses vary in protein 
and lipid composition and have different functions. 
For example, smaller HDL3 are relatively enriched in 
apoA-II.[12] Importantly, HDL2 and HDL3 have distinct 
INTRODUCTION
Cardiovascular disease (CVD) is the number one killer 
disease in the United States and most other developed 
countries.[1] Plasma level of cholesterol is the key indicator 
for the risk of developing CVD. Low-density lipoprotein 
cholesterol (LDL-C) and high-density lipoprotein 
cholesterol (HDL-C) levels are two independent risk 
factors.[2,3] High concentration of LDL-C is strongly 
associated with cardiovascular disease. In contrast, 
HDL-C correlates inversely with the risk of CVD.[2,3] 
The National Cholesterol Education Program (NCEP) 
Adult Treatment Panel III guidelines have recognized 
low HDL-C (<40 mg/dL) as an independent major risk 
factor for CVD.[4] Currently, statins are the most widely 
used drugs in modifying the cholesterol level. Statins 
inhibit 3-hydroxy-3-methyglutaryl-coenzyme A (HMG-
CoA) reductase activity, and, thus, inhibits cholesterol 
synthesis in the liver.[5] As a result, expression of LDL 
receptors is boosted to facilitate the removal of LDL 
from circulation.[5] Therefore, it is believed that the anti-
atherosclerotic function of statins is mainly due to their 
abilities to lower plasma LDL-C.[6,7] However, despite 
the wide use of statins, CVD remains the leading cause 
of death in industrialized countries. Therefore, other 
lipid-modifying therapeutic strategies are being sought to 
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functional and metabolic properties. Large HDL2 are 
believed to be more atheroprotective than small HDL3, 
because epidemiologic studies show that, compared with 
healthy individuals, patients with high risks of CVD 
often have higher levels of small HDL3 but lower level 
of large HDL2.[13] Also, HDL2 have been reported to have 
an enhanced ability to mediate cholesterol ester uptake 
via the scavenger receptor type B1 (SR-B1),[14] which is 
expected to contribute to their cardioprotective action.
HDL protect against atherosclerosis mainly by playing 
a central role in reverse cholesterol transport (RCT). 
RCT involves removal of cholesterol from arterial 
macrophages and delivery of this excess cholesterol to the 
liver for excretion or to steroidogenic organs for hormone 
synthesis, thereby preventing the formation of arterial 
plaques.[15] Since RCT is the only cholesterol-removal 
pathway in human, the role of HDL in cadioprotection 
is indispensable. Cholesterol efﬂ  ux mediated by lipid-
free or lipid-poor apoA-I through ABCA1 is the most 
efﬁ  cient cholesterol removal pathway.[16] In the presence 
of lecithin:cholesterol acyltransferase (LCAT), cholesterol 
in HDL surface is esteriﬁ  ed. The apolar molecules of 
cholesterol ester move from the surface to the core of the 
particle. As a result, mature HDL acquire their spherical 
shapes. Small spherical HDL3 can take up additional 
cholesterol and are further remodeled by LCAT and 
other plasma factors. Subsequently, they fuse into larger 
HDL2. HDL ﬁ  nally deliver their cargo of cholesterol to 
the liver for excretion through scavenger receptor class B 
type I (SR-BI). Although lipid-free or lipid-poor apoA-I 
is the primary cell cholesterol acceptor, spherical HDL 
also pick up cholesterol from peripheral tissues. Several 
ABC transporters, including ABCG1 and ABCG4, are 
involved in cholesterol efﬂ  ux from macrophages to HDL2 
and HDL3.
[17] Moreover, SR-BI is proposed to mediate 
bidirectional ﬂ  ux of cholesterol between mature HDL 
and cells. Thus, SR-BI can promote cholesterol efﬂ  ux into 
HDL when a concentration gradient exists.[11] 
In addition to their central role in RCT, HDL also have 
antioxidant, anti-inflammatory and anti-thrombotic 
properties, which contributes to their anti-atherogenic 
action. The anti-oxidant property of HDL is mainly due to 
their ability to inhibit LDL oxidation and remove oxidized 
lipids from LDL. According to the oxidation hypothesis 
of atherogenesis, oxidized LDL is more readily taken up 
by macrophages, which promotes foam cell formation. 
Therefore, deoxidization of LDL can decrease the risk of 
arterial plaque formation.
The anti-inﬂ  ammatory property of HDL is due to their 
ability to inhibit the expression of adhesion molecules, such 
as vascular cell adhesion molecule 1, intercellular adhesion 
molecule 1, and E-selection,[18] thereby inhibiting monocyte 
adhesion to endothelial cells, inﬁ  ltration into the arterial 
wall, and maturation to macrophage. The mechanism 
of inhibition may involve apoA-I, apoA-II, apoA-IV, 
and phospholipids such as sphigosine-1-phosphate and 
sphingosylphosphorylcholine.[18] As oxidized lipids are 
pro-inﬂ  ammatory,[19] the ability of HDL to remove these 
lipids also contributes to their anti-inﬂ  ammatory action.
The anti-thrombotic action of HDL is due to the inhibition 
of factors that promote blood coagulation, including factors 
X, Va, and VIIIa. This inhibition may result from anionic 
HDL lipids cardiolipin and phosphatidylethanolamine, 
which have anticoagulant properties.[11]
HDL-BASED THERAPIES
Statins have been reported to moderately increase the 
HDL-C level by 3–13%.[20] This HDL-C increasing effect 
is signiﬁ  cantly smaller than the statin-induced LDL-C 
lowering effect. Thus, the benefits of statin-induced 
HDL-C elevation are unclear and statins normally are not 
considered as HDL-raising drugs. Currently, niacin and 
ﬁ  brates are the main HDL-targeting therapies.
Niacin
To date, niacin (Nicotinic acid, Vitamin B3) is the most 
effective drug in the market to increase HDL-C (by 
15–30%).[21] Although niacin is available from many 
dietary sources, only high dose of niacin (1.5–2 g/day) 
has HDL-C elevation effects.[22] Many clinical trials have 
demonstrated that the niacin-induced increase in HDL-C 
level is associated with reduced risk of CVD. These 
clinical trails include Coronary Drug Project (CDP),[23] 
Familial Atherosclerosis Treatment Study (FATS),[24] 
HDL Atherosclerosis Treatment Study (HATS),[25] and, 
more recently, the randomized Arterial Biology for the 
Investigation of the Treatment Effects of Reducing 
Cholesterol Trials (ARBITER-2 and ARBITER-3).[26,27]
The beneﬁ  cial effect of niacin in modifying cholesterol 
levels was discovered 50 years ago,[28] but the underlying 
mechanism began to be elucidated only recently. Niacin 
activates the niacin receptor HM74A (GPR109B) in 
adipocytes, which inhibits adenylyl cyclase. Consequently, 
the amount of free fatty acid released from adipocytes 
to circulation is decreased, which leads to diminished 
plasma and hepatic triglyceride levels. As a result, HDL-C 
is increased.[29] However, the side effect of flushing 
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compromised the wide use of niacin. Extended-release 
(ER) formulations of niacin, which cause less ﬂ  ushing 
because of slower release of niacin, are available, but some 
of them seem to have increased liver toxicity. [30] Niacin 
causes ﬂ  ushing by elevating the synthesis of prostaglandin 
D2, which activates DP1 receptor and thus acts as a 
vasodilator.  [31] Laropiprant, a DP1 antagonist, was 
developed by Merck & Co.  for use in combination with 
niacin to minimize ﬂ  ushing. Laropiprant was approved 
by the European Medicines Agency, but not by the FDA, 
since administration of 325 mg aspirin, a widely used 
non-steroidal antiinﬂ  ammatory drug, 30–60 min before 
niacin can also reduce ﬂ  ushing.[32]
Fibrates
Fibrates are the other HDL-C raising drugs (by 5–20%) 
in the market. Fibrates indirectly raise plasma HDL level 
and lower triglyceride concentration through activating 
nuclear transcription factor PPARα. It has been proposed 
that ﬁ  brates increase HDL level through upregulation of 
apoA-I and ABCA1 and downregulation of SR-B1. Many 
clinical trials showed that ﬁ  brates are beneﬁ  cial for both 
primary and secondary prevention of CVDs, including 
the Helsinki Heart Study (HHS) (600 mg of gemﬁ  brozil 
twice daily) and Veterans Affairs HDL Intervention Trial 
(VA-HIT) (1.2 g/day gemﬁ  brozil).[33,34] However, effects 
of ﬁ  brates on CVD seem to be uncertain; for example, 
the Fenofibrate Intervention and Event Lowering in 
Diabetes (FIELD) trial (fenoﬁ  brate 200 mg/day) failed to 
demonstrate beneﬁ  cial effects of ﬁ  brates.[35]
FUTURE DIRECTIONS FOR HDL-BASED DRUGS
ApoA-I mimetic peptides
ApoA-I mimetic peptides are amphipathic peptides of 
18–22 amino acids, which mimic the lipid-binding domain 
of apoA-I. ApoA-I mimetics retain functional properties 
of apoA-I, such as the ability to form complexes with 
lipids, promote cell cholesterol efflux, and activate 
LCAT.[36] The advantage of mimetic peptides over the 
full-length apoA-I is that they are relatively easy and 
cheap to synthesize. D4F, an orally active peptide with 
D-amino acids (to avoid proteolysis by gut peptidases 
that recognize L-amino acids) and 4 phenylalanine 
substitutions, has been shown to enhance the anti-oxidant 
and anti-inﬂ  ammatory function of HDL and improve 
its cholesterol efﬂ  ux ability without increasing plasma 
HDL-C levels in mouse models.[36] However, D4F seems 
to show toxicity in human trials.
CETP inhibitor
Cholesterol ester transfer protein (CETP) mediates 
equimolar exchange of cholesterol ester for triglyceride 
among HDL and the triglyceride-rich apoB-containing 
lipoproteins (VLDL, IDL, LDL, chylomicrons, and their 
remnants).[37] The net effect of CETP action on HDL is 
enrichment with triglyceride and depletion of cholesterol 
ester.[37] As CETP reduces the HDL-C level, therapeutic 
approaches targeting CETP inhibition have been of interest 
for years.[37] Indeed, humans with CETP deﬁ  ciency have 
higher levels of HDL-C and apoA-I and tend to have 
lower rates of atherosclerosis.[38] However, the clinical 
trials of torcetrapib, a CETP inhibitor developed by 
Pﬁ  zer, were halted in 2006 due to an interim ﬁ  nding of 
Investigation of Lipid Level Management to Understand 
Its Impact in Atherosclerotic Events (ILLUMINATE) trail.
[39] Even though torcetrapib elevated the HDL-C level, it 
unexpectedly increased the risk for atherosclerotic events 
and led to a higher incidence of cardiovascular and non-
cardiovascular death.[39] It is not entirely clear whether 
the increased cardiovascular risk was due to the CETP 
inhibition or to the off-target effects of torcetrapib.[40] 
Currently, two other CETP inhibitors, Dalcetrapib (JTT-
705) and Anacetrapib (MK-0859), are still in clinical trials. 
In contrast to torcetrapib, Dalcetrapib and Anacetrapib 
increase HDL-C without increasing blood pressure, but 
further clinical trials are required to evaluate their efﬁ  cacy 
and safety.[41,42]
The failure of torcetrapib suggests that raising HDL-C 
levels alone may not necessarily provide protection from 
atherosclerosis.[13] Growing clinical evidence suggests 
that both HDL quantity and quality are important for 
cardioprotection. Epidemiological studies show that larger 
HDL are more cardioprotective than smaller HDL.[13] 
Functional studies revealed that mild oxidation beneﬁ  ts 
HDL function in cholesterol efflux while extensive 
oxidation impairs this function.[43] Studies by Gursky 
and colleagues suggest that less stable HDL has better 
functional properties and is more cardioprotective.[44-46] 
Therefore, measuring HDL stability may provide a simple 
way to assess HDL quality.
Lipase inhibitors
Hepatic lipase (HL)[7] and endothelial lipase (EL) can 
hydrolyze HDL triglycerides and phospholipids, leading to 
generation of lipid-poor apoA-I, which is susceptible to 
degradation. Thus, inhibition of HL and EL was proposed 
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to increase the plasma HDL level.[13,47] However, HL can 
also clear atherogenic apoB-containing particles; therefore, 
therapeutic strategies involving HL inhibition should be 
treated with caution. On the other hand, elevated EL levels 
are reportedly associated with atherosclerosis in humans.
[47] More research is needed to determine the potential of 
using EL inhibitors to raise the plasma level of HDL.
Liver X receptor agonists
Liver X receptor(LXR), one of the ligand-activated 
transcription factors, belongs to the nuclear receptor 
family. LXR regulates genes in cholesterol efﬂ  ux (ABCA1, 
ABCG1, ABCG4), genes in HDL remodeling (CETP 
and phospholipid transfer protein), genes in cholesterol 
secretion and bile-acid synthesis, and genes in hepatic 
lipogenesis.[30] Animal studies have shown that LXR 
activation leads to elevated HDL-C, and also elevated 
triglycerides, which may lead to the development of 
fatty liver.[13,48] Thus, the ideal LXR agonist would 
selectively upregulate ABCA1 and ABCG transporters 
in macrophages to promote reverse cholesterol transport 
and selectively upregulate genes in cholesterol secretion 
without activating genes in hepatic lipogenesis. LXRs have 
two isoforms, LXRα and LXRβ. LXRα is more abundant 
in the liver while LXRβ is ubiquitously expressed. Thus, 
selective modulation of LXRβ but not LXRα may lead 
to elevated HDL-C levels without the risk of developing 
hypertriglyceridemia and fatty liver.
CONCLUSIONS
LDL-C reducing drugs have been clinically used for 
decades, but the incidence of CVD is still high. Thus, 
increasing HDL level to complement statins, the LDL-
lowering drugs, became an attractive target. Despite 
vigorous efforts, HDL-modifying drugs are still not 
effective in decreasing mortality. In addition, the failure of 
CETP inhibitor torcetrapib casts a shadow on HDL-based 
drug development. Most HDL-based drug development 
efforts were focused on HDL-C increase. Recent studies 
showed that both the quantity and the quality of HDL 
are important for cardioprotection. It is possible that 
improving various aspects of HDL function will become 
a new direction for the development of HDL-based 
therapies in the future. Thus, not only increasing HDL-C 
level but also increasing functionally improved HDL may 
be a more effective strategy for CVD treatment.
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